# Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants

> **NCT07726914** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sanofi** · enrollment: 58 (estimated)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Belumosudil
- **DRUG:** Belumosudil

## Key facts

- **NCT ID:** NCT07726914
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-06
- **Primary completion:** 2026-09-28
- **Final completion:** 2026-09-28
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726914, "Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07726914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*